Shares of Loxo Oncology Inc. (NASDAQ:LOXO) fell 3.5% during trading on Friday . The stock traded as low as $24.52 and last traded at $24.88, with a volume of 61,381 shares traded. The stock had previously closed at $25.77.

Several brokerages have commented on LOXO. Zacks Investment Research lowered shares of Loxo Oncology from a “buy” rating to a “hold” rating in a research report on Saturday, August 6th. Cowen and Company reaffirmed a “buy” rating on shares of Loxo Oncology in a research report on Wednesday, July 13th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Loxo Oncology has a consensus rating of “Buy” and an average price target of $29.60.

The firm’s market cap is $539.00 million. The stock’s 50 day moving average is $25.51 and its 200-day moving average is $23.75.

Loxo Oncology (NASDAQ:LOXO) last issued its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by $0.14. On average, equities research analysts expect that Loxo Oncology Inc. will post ($2.83) EPS for the current year.

In related news, Director Keith T. Flaherty sold 15,000 shares of the stock in a transaction dated Thursday, August 11th. The shares were sold at an average price of $26.00, for a total transaction of $390,000.00. Following the sale, the director now directly owns 60,482 shares of the company’s stock, valued at approximately $1,572,532. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David P. Bonita sold 447,857 shares of the stock in a transaction dated Wednesday, August 10th. The shares were sold at an average price of $26.96, for a total transaction of $12,074,224.72. The disclosure for this sale can be found here.

Loxo Oncology, Inc is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.